Pricing

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

By

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

By

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Thursday, December 1, 2016

Five things for pharma marketers to know: Thursday, December 1, 2016

By

Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election

The New Reality for Pharma Marketers is Drug Pricing

The New Reality for Pharma Marketers is Drug Pricing

By

My hope is that all of us do a better job of focusing on value.

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

By

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

By

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

By

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

Five things for pharma marketers to know: Friday, November 4, 2016

Five things for pharma marketers to know: Friday, November 4, 2016

By

Pharma may face price-collusion charges; FDA approval team can't fill vacancies; OPDP issues letter over promo video

Timeline of a crisis: How Mylan responded to the EpiPen controversy

Timeline of a crisis: How Mylan responded to the EpiPen controversy

By

Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike — its response was seen as too little, too late.

Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

By

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Five things for pharma marketers to know: Tuesday, November 1, 2016

Five things for pharma marketers to know: Tuesday, November 1, 2016

By

Facebook opens up to pharma; Pfizer nixes PCSK9 inhibitor in development; Cardinal Health cuts forecast on dwindling price increases

Five things for pharma marketers to know: Monday, October 31, 2016

Five things for pharma marketers to know: Monday, October 31, 2016

By

Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed

Five things for pharma marketers to know: Wednesday, October 26, 2016

Five things for pharma marketers to know: Wednesday, October 26, 2016

By

Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed

J&J exec calls California pricing measure 'misguided'

J&J exec calls California pricing measure 'misguided'

By

Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.

Will Investors Reward Drugmakers That Limit Price Increases?

Will Investors Reward Drugmakers That Limit Price Increases?

By

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

Five things for pharma marketers to know: Friday, October 21, 2016

Five things for pharma marketers to know: Friday, October 21, 2016

By

Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand

Five things for pharma marketers to know: Monday, October 17, 2016

Five things for pharma marketers to know: Monday, October 17, 2016

By

Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs

Cleveland Clinic's Cosgrove: Obamacare now 'part of the fabric' of the U.S.

Cleveland Clinic's Cosgrove: Obamacare now 'part of the fabric' of the U.S.

By

Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in

Five things for pharma marketers to know: Wednesday, October 12, 2016

Five things for pharma marketers to know: Wednesday, October 12, 2016

By

Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs

How five therapies changed the course of pharma history

How five therapies changed the course of pharma history

By

And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.

Five things for pharma marketers to know: Wednesday, September 28, 2016

Five things for pharma marketers to know: Wednesday, September 28, 2016

By

Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry

The EpiPen Debate Reveals Gap in Industry's Pricing Defense

The EpiPen Debate Reveals Gap in Industry's Pricing Defense

"Standard economic concerns like price elasticity fall out of the equation when people simply have no choices. No one buys an EpiPen for fun," Dr. David Katz writes.

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.

McCann Health forms new global consultancy

McCann Health forms new global consultancy

By

The consultancy includes Double Helix, which was acquired by McCann in 2012.

Five things for pharma marketers to know: Monday, September 19, 2016

Five things for pharma marketers to know: Monday, September 19, 2016

By

Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study

Five things for pharma marketers to know: Thursday, September 15, 2016

Five things for pharma marketers to know: Thursday, September 15, 2016

By

Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness

Five things for pharma marketers to know: Wednesday, September 7, 2016

Five things for pharma marketers to know: Wednesday, September 7, 2016

By

BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan

CEO: Allergan will limit price increases for branded drugs

CEO: Allergan will limit price increases for branded drugs

By

CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.

OPINION

Email Newsletters